Collaborations among academia, government, and industry in the diagnostics space: barriers and some ideas for solutions.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 21178133.
- Also identified by DOI 10.1126/scitranslmed.3001633.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The development and commercialization of diagnostic assays is distinct from that of therapeutic drugs in many important respects; for example, there are more variable regulatory requirements and reduced outside investments for diagnostics. The diagnostics industry has a pro-collaborative stance, because there is considerable mutual benefit in working in partnership with university or government researchers. However, there are substantial barriers to industry-academic collaborations. A Clinical and Translational Science Awards Industry Forum titled "Promoting Efficient and Effective Collaborations Among Academia, Government, and Industry" was held in February 2010, and a session at this forum was organized to list some of the most important barriers to diagnostics development and to discuss some possible solutions.
Medical subject headings
- Government
- Industry
- Interdisciplinary Communication
- Translational Research, Biomedical